A peer-reviewed study of more than 46,000 older adults with type 2 diabetes found that patients who startedGLP-1receptoragonistdrugs faced an 11 percent higherriskof fragilityfractures...
Tan Y, Liu S, Tang Q. Effect ofGLP-1receptoragonistson bone mineral density, bone metabolism markers, andfractureriskin type 2 diabetes: a systematic review and meta-analysis.
Objective The aim of this study was to assess theriskof fragilityfracturesassociated withGLP-1RA therapy compared to sodium-glucose cotransporter-2 inhibitors or dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes.
Abstract Introduction: Glucagon-like peptide-1 receptoragonists(GLP-1RA) are prescribed for glycemic control and weight reduction. Little is known regarding the impact ofGLP-1RAs on bone health in patients without diabetes.
A large study in older adults with type 2 diabetes finds thatGLP-1receptoragonistsare associated with a modestly increasedriskof bonefracturescompared to other diabetes treatments.
Furthermore, visual representations like the one above help us fully grasp the concept of Fracture Risk With Glp-1 Agonist.
In older adults with type 2 diabetes (T2D), the initiation ofGLP-1receptoragonistsvs drugs such as DPP-4 and SGLT2 inhibitors was associated with an 11% increasedriskfor fragilityfractures.
Aim To systematically assess randomized controlled trials that evaluated the effect of glucagon-like peptide-1 (GLP-1) receptoragonistsonfractureincidence, bone mineral density, and bone metabolism markers in individuals with type 2 diabetes. Methods From database setup to March 21, 2024, a search was conducted across nine Chinese and English databases. The CochraneRiskof Bias Tool was ...
